CLINICAL_TRIALS ClinicalTrials.gov record update

Gemcitabine Plus Nab-PAclitaxel as Switch maiNTEnance Versus cONtinuation of Modified FOLFIRINOX as First-line Chemotherapy in Patients With Advanced Pancreatic Cancer: the PANThEON Phase III Trial

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06897644
Title field or adapter rule: {'original_value': 'Gemcitabine Plus Nab-PAclitaxel as Switch maiNTEnance Versus cONtinuation of Modified FOLFIRINOX as First-line Chemotherapy in Patients With Advanced Pancreatic Cancer: the PANThEON Phase III Trial', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:26.373994+00:00
Published At: 2026-09-09T00:00:00+00:00
Record Updated At: 2026-09-09
Source Retrieved At: 2026-10-31T22:17:56.788771+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

protocolSection.conditionsModule.conditions: ["Pancreatic Adenocarcinoma Advanced or Metastatic"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-09-09", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT06897644"
protocolSection.identificationModule.officialTitle: "Gemcitabine Plus Nab-PAclitaxel as Switch maiNTEnance Versus cONtinuation of Modified FOLFIRINOX as First-line Chemotherapy in Patients With Advanced Pancreatic Cancer: the PANThEON Phase III Trial"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

{'armGroupLabels': ['ARM A - continuation of mFOLFIRINOX'], 'description': '85 mg/sqm iv over 2 hours day 1', 'name': 'Oxaliplatin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['ARM A - continuation of mFOLFIRINOX'], 'description': '150 mg/sqm iv over 60 minutes day 1', 'name': 'Irinotecan (CPT-11)', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['ARM A - continuation of mFOLFIRINOX'], 'description': 'Leucovorin 400 mg/sqm (racemic) or l-Leucovorin 200 mg/sqm over 2 hours day 1', 'name': 'Leucovorin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['ARM A - continuation of mFOLFIRINOX'], 'description': '2400 mg/sqm 46-hours infusion', 'name': '5-FU (5-fluorouracil)', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['ARM B - switch maintenance with Gem-NabP'], 'description': '1000 mg/sqm over 30 minutes on Days 1,8,15 of a 28-day cycles', 'name': 'gemcitabine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['ARM B - switch maintenance with Gem-NabP'], 'description': '125 mg/sqm over 30 minutes on Days 1,8,15 of a 28-day cycles', 'name': 'Nab-paclitaxel', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.